[
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)",
    "summary": "Get the latest on Gilead Sciences' growth, HIV and oncology pipeline, and PrEP innovation",
    "url": "https://finnhub.io/api/news?id=511b7cf76af66814d0b8a34fbb368821ffd0b09776c6215efc10b8c9f81b14b7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757427394,
      "headline": "Gilead Sciences, Inc. (GILD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)",
      "id": 136678415,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Get the latest on Gilead Sciences' growth, HIV and oncology pipeline, and PrEP innovation",
      "url": "https://finnhub.io/api/news?id=511b7cf76af66814d0b8a34fbb368821ffd0b09776c6215efc10b8c9f81b14b7"
    }
  },
  {
    "ts": null,
    "headline": "Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies",
    "summary": "CAMBRIDGE, Mass., September 09, 2025--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development.",
    "url": "https://finnhub.io/api/news?id=a0ba38c0d10020d162034920906f6a3aa6e51e063d0497a1283c551f40c49dd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757424600,
      "headline": "Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies",
      "id": 136689334,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, Mass., September 09, 2025--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development.",
      "url": "https://finnhub.io/api/news?id=a0ba38c0d10020d162034920906f6a3aa6e51e063d0497a1283c551f40c49dd8"
    }
  },
  {
    "ts": null,
    "headline": "What the Trump Administration Partnership Means for Gilead Sciences Shares in 2025",
    "summary": "Considering what to do with Gilead Sciences stock right now? You are not alone. With shares closing at $115.88 and the company logging a robust 26.1% return since the start of the year, investors are balancing optimism with a healthy dose of caution. If you have watched Gilead, you have likely noticed its 90.5% return over three years and a stunning 111.2% over five. Clearly, something interesting is happening beneath the surface. The story in the headlines has been dramatic as well. Gilead’s...",
    "url": "https://finnhub.io/api/news?id=f25edbfbeb6af55223b18ecb8d44f15e7cac00a88d1a5aaa54a12e151a04396f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757418436,
      "headline": "What the Trump Administration Partnership Means for Gilead Sciences Shares in 2025",
      "id": 136687343,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Considering what to do with Gilead Sciences stock right now? You are not alone. With shares closing at $115.88 and the company logging a robust 26.1% return since the start of the year, investors are balancing optimism with a healthy dose of caution. If you have watched Gilead, you have likely noticed its 90.5% return over three years and a stunning 111.2% over five. Clearly, something interesting is happening beneath the surface. The story in the headlines has been dramatic as well. Gilead’s...",
      "url": "https://finnhub.io/api/news?id=f25edbfbeb6af55223b18ecb8d44f15e7cac00a88d1a5aaa54a12e151a04396f"
    }
  },
  {
    "ts": null,
    "headline": "Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead",
    "summary": "Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the initiation of patient dosing in Phase 2",
    "url": "https://finnhub.io/api/news?id=6221edcc9f907dc5afcb8f0632440513cc62e5da176d31a02ce32b186474fa12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757421000,
      "headline": "Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead",
      "id": 136689336,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the initiation of patient dosing in Phase 2",
      "url": "https://finnhub.io/api/news?id=6221edcc9f907dc5afcb8f0632440513cc62e5da176d31a02ce32b186474fa12"
    }
  },
  {
    "ts": null,
    "headline": "Hepatitis D Market Research Report 2023-2035 | Gilead, GSK, and Janssen Drive Innovation as Biotechs Advance Antivirals, RNA, and Gene Therapies",
    "summary": "The hepatitis D market is expanding due to increased diagnosis rates and advancements in treatment options. Hepatitis D, a severe liver disease linked to hepatitis B virus (HBV) infection, is prevalent in regions with high HBV rates. Advancements in diagnostic technologies, like nucleic acid testing and serological assays, are leading to early detection and improved patient outcomes. Recently approved therapies, including bulevirtide, are driving market growth by offering targeted treatment solu",
    "url": "https://finnhub.io/api/news?id=ec59c75430107bd21d302a1dbe23091c89b4d03777202e8e3e1d931c109a6583",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757417700,
      "headline": "Hepatitis D Market Research Report 2023-2035 | Gilead, GSK, and Janssen Drive Innovation as Biotechs Advance Antivirals, RNA, and Gene Therapies",
      "id": 136689337,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The hepatitis D market is expanding due to increased diagnosis rates and advancements in treatment options. Hepatitis D, a severe liver disease linked to hepatitis B virus (HBV) infection, is prevalent in regions with high HBV rates. Advancements in diagnostic technologies, like nucleic acid testing and serological assays, are leading to early detection and improved patient outcomes. Recently approved therapies, including bulevirtide, are driving market growth by offering targeted treatment solu",
      "url": "https://finnhub.io/api/news?id=ec59c75430107bd21d302a1dbe23091c89b4d03777202e8e3e1d931c109a6583"
    }
  }
]